Synthesis and evaluation of a pyrazinoic acid prodrug in Mycobacterium tuberculosis


Autoria(s): Fernandes, Joao Paulo-dos Santos; Pavan, Fernando Rogério; Leite, Clarice Queico Fujimura; Andres Felli, Veni Maria
Contribuinte(s)

Universidade Estadual Paulista (UNESP)

Data(s)

18/03/2015

18/03/2015

01/09/2014

Resumo

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)

Tuberculosis (TB) is a disease caused mainly by infection of Mycobacterium tuberculosis affecting more than ten million people around the world. Despite TB can be treated, the rise of MDR-TB and XDR-TB cases put the disease in a worrying status. As pyrazinamide-resistant strains exhibit low or none pyrazinamidase activity, it is proposed that the active form of pyrazinamide (PZA) is pyrazinoic acid (POA), although this acid has poor penetration in mycobacteria. In this work, we present a convenient one-pot synthesis of 2-chloroethyl pyrazinoate, and its activity in M. tuberculosis H(37)Rv (ATCC27294) in MIC assay using the MABA technique. The obtained MIC of the compound was 3.96 g/mL, and discussion about the activity profile of some previously evaluated pyrazinoates is also performed. (C) 2013 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.

Formato

376-380

Identificador

http://dx.doi.org/10.1016/j.jsps.2013.12.005

Saudi Pharmaceutical Journal. Amsterdam: Elsevier Science Bv, v. 22, n. 4, p. 376-380, 2014.

1319-0164

http://hdl.handle.net/11449/116638

10.1016/j.jsps.2013.12.005

WOS:000341120900013

WOS000341120900013.pdf

Idioma(s)

eng

Publicador

Elsevier B.V.

Relação

Saudi Pharmaceutical Journal

Direitos

openAccess

Palavras-Chave #Antimycobacterial agent #Ester synthesis #Prodrug #Pyrazinoic acid #Tuberculostatic
Tipo

info:eu-repo/semantics/article